BASKING RIDGE, N.J.--(BUSINESS WIRE)--Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced key hires as the company continues to build its executive management capabilities. The company has identified bolstering its presence in North America as a key strategic priority, and these additions to the senior leadership team represent an integral move forward in executing Ipsen’s continued growth.
“The addition of Dr. Dennis Kim as our SVP of North American Medical and Regulatory Affairs, and David Cox, PhD, as VP of Medical Affairs, will provide us with the experience and expertise to build and support our growing presence in oncology, endocrinology and neurology,” said Cynthia Schwalm, President and CEO, Ipsen Biopharmaceuticals. “Lynda Parker is spearheading our efforts to implement our oncology commercialization strategy as well as building and supporting our endocrinology commercial team. We will continue to add key members as we expand our North American footprint as a leading specialty biopharmaceutical company. ”
New Hires Include:
Dennis Kim, MD, MPH – Senior Vice President, North American Medical
and Regulatory Affairs:
Dr. Kim will provide strategic direction and leadership for North American Medical Affairs, Drug Safety, and Regulatory Affairs for the Oncology, Endocrinology and Neurology franchises. Prior to joining Ipsen, he was the Vice President and Head, Medical Affairs for Spectrum Pharmaceuticals. Dr. Kim started his career at the Centers for Disease Control (CDC) as an Epidemic Intelligence Officer working in public health and epidemiology and also has worked at Amgen, Biogen Idec and Novartis. His experience has spanned multiple therapeutic areas including oncology, neurology, nephrology and immunology.
David Cox, PhD – Vice President, Medical Affairs Oncology and
Dr. Cox is responsible for leading medical affairs planning and activities for Ipsen's oncology and endocrinology portfolio in North America. He has spent the majority of his 14-year career in medical affairs and clinical development roles, working at Eisai Pharmaceuticals, Bristol-Myers Squibb, Galderma Pharmaceuticals and Precept Medical Communications. David was most recently the Americas Medical Strategy Lead at Eisai, managing medical directors and MSL teams, supporting the medical affairs strategy for the company’s oncology portfolio in North America. His therapeutic area experience also includes metabolics/cardiovascular and neurology and he has had extensive involvement with product launches, orphan diseases, and medical affairs team building/planning.
Lynda Parker – Vice President, Oncology & Endocrinology Business Unit:
Ms. Parker will be responsible for developing the strategy and leading commercial execution of plans for oncology and endocrinology products, including Ipsen Biopharmaceutical’s first oncology launch, expected in Neuroendocrine Cancer. Lynda brings more than 20 years of experience in sales, marketing and patient advocacy in therapeutic areas such as oncology, endocrinology, neurology and other specialty markets. She most recently worked at inVentiv Health where she was responsible for building and launching multiple sales teams and products.
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2013. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2013, R&D expenditure totaled close to €260 million, representing more than 21% of Group sales. Ipsen also has a significant presence in primary care. The Group has close to 4,600 employees worldwide. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.
Forward Looking Statement
The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today.
Use of the words "believes," "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from Generics that might translate into a loss of market share.
Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfill their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance.
The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law.
The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers.